RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and raises the price target from $44 to $53.
June 04, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Agios Pharmaceuticals and increased the price target from $44 to $53, indicating strong confidence in the company's future performance.
The increase in the price target from $44 to $53 by RBC Capital suggests a positive outlook for Agios Pharmaceuticals. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100